PROCEPT BioRobotics Corporation (PRCT) Stock Forecast
PRCT analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.47 / 5 from 15 analysts
- Price target
- $22.25 average of analyst targets
- Upside to target
- +26.6% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.39
- 52-week range
- $16.69 – $36.95
PRCT analyst ratings
15 analystsNumber of analysts at each rating.
PRCT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PRCT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.39 | −$0.42 | −$0.34 | −$0.38 | −2.5% | 11 |
| Current fiscal year (2026) | −$1.68 | −$1.82 | −$1.62 | −$1.72 | +2.2% | 12 |
| Next fiscal year (2027) | −$1.17 | −$1.53 | −$0.82 | −$1.68 | +30.3% | 12 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PRCT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $100.7M | $96.2M | $103.6M | +20.9% | 14 |
| Current fiscal year (2026) | $395.3M | $384.0M | $402.4M | +28.3% | 14 |
| Next fiscal year (2027) | $476.3M | $449.0M | $488.1M | +20.5% | 14 |
PRCT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PRCT revenue: reported and forecast
PRCT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.34 | −$0.39 | −$0.39 | −$0.39 | −$0.39 | +15.3% | 0 up · 9 down |
| Current fiscal year (2026) | −$1.54 | −$1.68 | −$1.68 | −$1.68 | −$1.68 | +9.2% | 0 up · 10 down |
| Next fiscal year (2027) | −$0.89 | −$1.15 | −$1.15 | −$1.17 | −$1.17 | +31.5% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PRCT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PRCT beat in 8 of 12.
What analysts expect from PRCT
15 analysts cover PROCEPT BioRobotics; their consensus rating is hold (3.47 on a 1–5 scale, where 5 is a strong buy). The average price target is $22.25, 26.6% above the latest close of $17.57. Analysts expect earnings of −$1.68 per share for 2026, +2.2% from a year earlier. For 2027 the average estimate is −$1.17 per share on revenue of $476.3 million. PROCEPT BioRobotics beat the EPS estimate in 8 of the last 12 quarters.
Related: PRCT income statement, PRCT key metrics, PRCT chart. See the PRCT stock overview for the latest quote and news.
PRCT forecast FAQ
What is PROCEPT BioRobotics's price target?
The average analyst price target for PROCEPT BioRobotics is $22.25, 26.6% above the latest close of $17.57.
Is PROCEPT BioRobotics a buy, hold or sell?
Of 15 analysts covering PROCEPT BioRobotics, 3 rate it a strong buy, 2 a buy, 9 a hold, 1 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is PROCEPT BioRobotics's EPS forecast?
Analysts forecast −$1.68 per share for 2026 (range −$1.82 to −$1.62); for 2027 the estimate is −$1.17.
What is PROCEPT BioRobotics's revenue forecast?
The average revenue estimate for 2026 is $395.3 million, growth of 28.3%; for 2027 it is $476.3 million.
When does PROCEPT BioRobotics report earnings?
PROCEPT BioRobotics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $-0.39.
Does PROCEPT BioRobotics usually beat earnings estimates?
PROCEPT BioRobotics reported EPS at or above the analyst estimate in 8 of the last 12 quarters.